Soo Jie Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Soo Jie Chung has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Jeong-Hee Choi
Department of Pulmonology and Allergy Hallym University Dongtan Sacred Heart Hospital Hwaseong Korea
5 shared publications - Hye-Ryun Kang
Drug safety Center, Seoul National University Hospital, Seoul, Korea
4 shared publications - Sung-Yoon Kang
Division of Pulmonology and Allergy, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea
4 shared publications - Bong-Seong Kim
Department of Pediatrics, GangNeung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea
2 shared publications - Do Hyun Kim
Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
2 shared publications - Do-Yang Park
Department of Otolaryngology, Ajou University School of Medicine, Suwon 16499, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (5) , 776-792
Genome-Wide Risk Assessment and Clinical Prediction of Iodinated Contrast Media–Induced Anaphylaxis
Chung SJ, et al. Allergy Asthma Immunol Res. 2026 Sep;18(5):776-792. https://doi.org/10.4168/aair.2026.18.5.776
- 1 January 2026
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 18 (5) , 776-792
Open AccessGenome-Wide Risk Assessment and Clinical Prediction of Iodinated Contrast Media–Induced Anaphylaxis
Chung SJ, et al. Allergy Asthma Immunol Res. 2026 Sep;18(5):776-792. https://doi.org/10.4168/aair.2026.18.5.776
- Open Access
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (5) , 695-698
A Case Series of Chronic Spontaneous Urticaria After COVID-19 Vaccination
Choi JH, et al. Allergy Asthma Immunol Res. 2023 Sep;15(5):695-698. https://doi.org/10.4168/aair.2023.15.5.695
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (5) , 695-698
Open AccessA Case Series of Chronic Spontaneous Urticaria After COVID-19 Vaccination
Choi JH, et al. Allergy Asthma Immunol Res. 2023 Sep;15(5):695-698. https://doi.org/10.4168/aair.2023.15.5.695
- Open Access
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (2) , 145-159
KAAACI Allergic Rhinitis Guidelines: Part 2. Update in Non-pharmacological Management
Park DY, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):145-159. https://doi.org/10.4168/aair.2023.15.2.145
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (2) , 145-159
Open AccessKAAACI Allergic Rhinitis Guidelines: Part 2. Update in Non-pharmacological Management
Park DY, et al. Allergy Asthma Immunol Res. 2023 Mar;15(2):145-159. https://doi.org/10.4168/aair.2023.15.2.145
- Open Access
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (1) , 19-31
KAAACI Allergic Rhinitis Guidelines: Part 1. Update in Pharmacotherapy
Yang SI, et al. Allergy Asthma Immunol Res. 2023 Jan;15(1):19-31. https://doi.org/10.4168/aair.2023.15.1.19
- 1 January 2023
- Published by XMLink in Allergy, Asthma & Immunology Research
- Vol. 15 (1) , 19-31
Open AccessKAAACI Allergic Rhinitis Guidelines: Part 1. Update in Pharmacotherapy
Yang SI, et al. Allergy Asthma Immunol Res. 2023 Jan;15(1):19-31. https://doi.org/10.4168/aair.2023.15.1.19
- 13 June 2022
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 36 (9) , 1041-1050
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019
Background: Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials. However, there have been few reports on large-scale epidemiological studies on the adverse effects of antipsychotics in Asia. Aim: This study aimed to investigate the characteristics of antipsychotic ADRs using a nationwide pharmacovigilance database. Methods: Data were collected from the Korea Adverse Event Reporting System database between 2010 and 2019. The study subjects were selected using the International Classification of Disease codes for diseases related to psychosis and Electronic Data Interchange codes for amisulpride, aripiprazole, clozapine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. The causality assessment of “possible,” “probable,” or “certain” by the World Health Organization–Uppsala Monitoring Center System causality category was selected. All data were descriptively analyzed. Results: In total, 5067 adverse events associated with antipsychotic drugs were reported. The antipsychotics that commonly resulted in ADRs were quetiapine (47.7%), olanzapine (11.3%), and clozapine (10.7%). Serious ADRs were most commonly observed with clozapine. Gastrointestinal and central nervous system problems occurred within a month when ADRs were classified according to the time of onset. In contrast, metabolic and bone marrow-related symptoms occurred after long-term use. Sedation and nausea were the most common ADRs in children and adolescents, whereas constipation and dizziness were common in adults and the elderly. Conclusions: This study extends our knowledge of antipsychotic ADRs in the Asian population.
- 13 June 2022
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 36 (9) , 1041-1050
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019
Background: Retrospective studies using spontaneous reporting system databases have provided a great understanding of adverse drug reactions (ADRs) in the real world, complementing the data obtained from randomized controlled trials. However, there have been few reports on large-scale epidemiological studies on the adverse effects of antipsychotics in Asia. Aim: This study aimed to investigate the characteristics of antipsychotic ADRs using a nationwide pharmacovigilance database. Methods: Data were collected from the Korea Adverse Event Reporting System database between 2010 and 2019. The study subjects were selected using the International Classification of Disease codes for diseases related to psychosis and Electronic Data Interchange codes for amisulpride, aripiprazole, clozapine, haloperidol, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone. The causality assessment of “possible,” “probable,” or “certain” by the World Health Organization–Uppsala Monitoring Center System causality category was selected. All data were descriptively analyzed. Results: In total, 5067 adverse events associated with antipsychotic drugs were reported. The antipsychotics that commonly resulted in ADRs were quetiapine (47.7%), olanzapine (11.3%), and clozapine (10.7%). Serious ADRs were most commonly observed with clozapine. Gastrointestinal and central nervous system problems occurred within a month when ADRs were classified according to the time of onset. In contrast, metabolic and bone marrow-related symptoms occurred after long-term use. Sedation and nausea were the most common ADRs in children and adolescents, whereas constipation and dizziness were common in adults and the elderly. Conclusions: This study extends our knowledge of antipsychotic ADRs in the Asian population.
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Clinical Neurology
- Vol. 18 (3) , 271-279
Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders
Mo H, et al. J Clin Neurol. 2022 May;18(3):271-279. https://doi.org/10.3988/jcn.2022.18.3.271
- 1 January 2022
- Published by XMLink in Journal of Clinical Neurology
- Vol. 18 (3) , 271-279
Open AccessOxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders
Mo H, et al. J Clin Neurol. 2022 May;18(3):271-279. https://doi.org/10.3988/jcn.2022.18.3.271
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (16) , e128
Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System
Chung SJ, et al. J Korean Med Sci. 2022 Apr;37(16):e128. https://doi.org/10.3346/jkms.2022.37.e128
- 1 January 2022
- Published by XMLink in Journal of Korean Medical Science
- Vol. 37 (16) , e128
Open AccessAnalysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System
Chung SJ, et al. J Korean Med Sci. 2022 Apr;37(16):e128. https://doi.org/10.3346/jkms.2022.37.e128
Novel tobacco products including electronic cigarette and heated tobacco products increase risk of allergic rhinitis and asthma in adolescents: Analysis of Korean youth survey
Background: The effect of novel tobacco products, such as electronic cigarettes (EC) and heated tobacco products (HTP), on allergic rhinitis (AR) and asthma is not well known.Objective: To evaluate the health effect of novel tobacco products on asthma and AR.Methods: This study was conducted using large survey data on Korean middle and high school students. The relationship between current asthma/AR and novel tobacco products user status was evaluated. In order to compare the combined effects of conventional cigarette (CC), EC, and HTP use on current allergic diseases, the participants were classified into 18 groups based on CC (current, former, and never), EC (current, former, and never), and HTP (ever and never) status.Results: A total of 60,040 participants representing 2,850,118 Korean adolescents were analyzed. Of all participants, 6.7%, 2.7%, and 2.9% were current CC, current EC, and ever HTP users, respectively. Current CC and ever HTP use was significantly associated with current asthma and AR in adjusted models. Current EC showed association with current AR but the association with asthma disappeared in the adjusted model. Among 18 groups, the groups including current CC use showed higher risk of current AR and asthma than never HTP‐never EC‐never CC group. The odds ratio of current asthma especially increased more in those who used EC and/or HTP with CC concurrently than those in the never HTP‐never EC‐current CC user group.Conclusion: Using EC and/or HTP in adolescents might enhance the adverse effect of CC on AR and asthma.
Novel tobacco products including electronic cigarette and heated tobacco products increase risk of allergic rhinitis and asthma in adolescents: Analysis of Korean youth survey
Background: The effect of novel tobacco products, such as electronic cigarettes (EC) and heated tobacco products (HTP), on allergic rhinitis (AR) and asthma is not well known.Objective: To evaluate the health effect of novel tobacco products on asthma and AR.Methods: This study was conducted using large survey data on Korean middle and high school students. The relationship between current asthma/AR and novel tobacco products user status was evaluated. In order to compare the combined effects of conventional cigarette (CC), EC, and HTP use on current allergic diseases, the participants were classified into 18 groups based on CC (current, former, and never), EC (current, former, and never), and HTP (ever and never) status.Results: A total of 60,040 participants representing 2,850,118 Korean adolescents were analyzed. Of all participants, 6.7%, 2.7%, and 2.9% were current CC, current EC, and ever HTP users, respectively. Current CC and ever HTP use was significantly associated with current asthma and AR in adjusted models. Current EC showed association with current AR but the association with asthma disappeared in the adjusted model. Among 18 groups, the groups including current CC use showed higher risk of current AR and asthma than never HTP‐never EC‐never CC group. The odds ratio of current asthma especially increased more in those who used EC and/or HTP with CC concurrently than those in the never HTP‐never EC‐current CC user group.Conclusion: Using EC and/or HTP in adolescents might enhance the adverse effect of CC on AR and asthma.
- Open Access
- 1 January 2020
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 12 (5) , 894-896
Omalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea
Kim JH, et al. Allergy Asthma Immunol Res. 2020 Sep;12(5):894-896. https://doi.org/10.4168/aair.2020.12.5.894
- 1 January 2020
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 12 (5) , 894-896
Open AccessOmalizumab Treatment in Patients With Cholinergic Urticaria: A Real-World Retrospective Study in Korea
Kim JH, et al. Allergy Asthma Immunol Res. 2020 Sep;12(5):894-896. https://doi.org/10.4168/aair.2020.12.5.894
- 13 August 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 82 (5) , 777-785
A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity
Desensitization is a safe alternative for patients with hypersensitivity reactions (HSRs) to platinum-based chemotherapeutic agents and widely used in real practice by employing stepwise administration of multiple serial dilutions of the culprit drugs. However, its labor-intensive nature has required a simpler protocol that is easier to prepare and perform. We performed an observational study of patients with platinum HSR who underwent a new non-dilution one-bag desensitization protocol. Premedication consisted of Montelukast as well as H1 and H2 blockers. The outcomes and safety profiles of a new protocol were assessed. A total of 36 patients were recruited (oxaliplatin 23, carboplatin 9, and cisplatin 4) and the most common grade of HSR presented was grade 2 (61.1%), followed by grade 3 (25%), and grade 1 (13.9%). Of 175 desensitization procedures, all cases were successfully completed in re-administration of culprit chemotherapeutic platinum agents; 146 (83.4%) had no breakthrough reactions (BTRs) while 29 (16.6%) did. Most BTRs were mild reactions (grade 1, 51.7%) or moderate reactions (grade 2, 44.8%) of Brown's Scale. Although there was one case of asymptomatic mild hypotension (grade 3, 3.5%), categorized as severe reaction, dyspnea, desaturation, and anaphylaxis did not occur. The proportion of severe HSRs was significantly lower than that of initial HSRs (3.5% vs. 25%, P = 0.0167). The new non-dilution desensitization protocol was safe and effective for re-administration of culprit platinum agents in patients with a history of HSRs. Therefore, this new protocol can be used as an alternative to existing protocols using multiple serial dilutions.
- 13 August 2018
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 82 (5) , 777-785
A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity
Desensitization is a safe alternative for patients with hypersensitivity reactions (HSRs) to platinum-based chemotherapeutic agents and widely used in real practice by employing stepwise administration of multiple serial dilutions of the culprit drugs. However, its labor-intensive nature has required a simpler protocol that is easier to prepare and perform. We performed an observational study of patients with platinum HSR who underwent a new non-dilution one-bag desensitization protocol. Premedication consisted of Montelukast as well as H1 and H2 blockers. The outcomes and safety profiles of a new protocol were assessed. A total of 36 patients were recruited (oxaliplatin 23, carboplatin 9, and cisplatin 4) and the most common grade of HSR presented was grade 2 (61.1%), followed by grade 3 (25%), and grade 1 (13.9%). Of 175 desensitization procedures, all cases were successfully completed in re-administration of culprit chemotherapeutic platinum agents; 146 (83.4%) had no breakthrough reactions (BTRs) while 29 (16.6%) did. Most BTRs were mild reactions (grade 1, 51.7%) or moderate reactions (grade 2, 44.8%) of Brown's Scale. Although there was one case of asymptomatic mild hypotension (grade 3, 3.5%), categorized as severe reaction, dyspnea, desaturation, and anaphylaxis did not occur. The proportion of severe HSRs was significantly lower than that of initial HSRs (3.5% vs. 25%, P = 0.0167). The new non-dilution desensitization protocol was safe and effective for re-administration of culprit platinum agents in patients with a history of HSRs. Therefore, this new protocol can be used as an alternative to existing protocols using multiple serial dilutions.